Who Paid My Doc
Obi Ihim
Diagnostic Radiology Washington, DC Medical Doctor
NPI 1447710280 CMS profile 11946151
3800 Reservoir Rd Nw, Washington, DC 20007
General payments
$3,714
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Obi Ihim of Washington, DC is reported in the CMS Open Payments database as having received $3,714 across 48 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 88th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,714 | 48 |
Beside peers
- Obi Ihim
- Diagnostic Radiology median
- Middle half of Diagnostic Radiology
- National median
In program year 2025, general payments to Obi Ihim were reported at $3,714. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.
Show as a table
| Year | Obi Ihim | Diagnostic Radiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $108 | $29–$318 | $163 |
| 2020 | $0 | $65 | $21–$252 | $114 |
| 2021 | $0 | $92 | $24–$292 | $132 |
| 2022 | $0 | $104 | $29–$294 | $149 |
| 2023 | $0 | $110 | $29–$337 | $160 |
| 2024 | $0 | $113 | $30–$356 | $164 |
| 2025 | $3,714 | $112 | $32–$349 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
25
Drug cost
$198
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ciprofloxacin Hcl | Generic | 13 | $155 | |
| Metronidazole | Generic | 12 | $43 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.
Records
48 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Diagnostic Radiology in District of Columbia
Rachel Brem
Diagnostic Radiology · Washington, DC
Jason Katzen
Diagnostic Radiology · Washington, DC
Nora McDermott-Tabori
Diagnostic Radiology · Washington, DC
Jocelyn Rapelyea
Diagnostic Radiology · Washington, DC
Brooke Wolvin
Diagnostic Radiology · Washington, DC
Andrew Hall
Diagnostic Radiology · Washington, DC
Related records
Diagnostic Radiology in District of Columbia
Practitioners in the same specialty and state, ranked by reported value.
All Diagnostic Radiology
Everyone recorded under this specialty, nationwide.
Doctors in District of Columbia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.